Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related TEVA
Oppenheimer: Teva Is Now Worth $77/Share, More Deals To Come
Benzinga's Volume Movers
Healthcare ETFs Rally on Monday Merger Mania - ETF News And Commentary (Zacks)
Related RVBD
JP Morgan Positive On Brocade Communications' Intent To Acquire SteelApp Assets
Riverbed Technology Beats Q4 EPS Expectations

Analysts at Canaccord downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “buy” to “hold.” The target price for Teva has been raised from $50 to $45. Teva's shares closed at $37.96 yesterday.

Analysts at FBR Capital downgraded Riverbed Technology (NASDAQ: RVBD) from “outperform” to “market perform.” The target price for Riverbed has been lowered from $28 to $20. Riverbed's shares closed at $20.10 yesterday.

Analysts at Roth Capital downgraded Skullcandy (NASDAQ: SKUL) from “buy” to “neutral.” The target price for Skullcandy is set to $7. Skullcandy's shares closed at $6.61 yesterday.

CRT Capital downgraded Alpha Natural Resources (NYSE: ANR) from “buy” to “fair value.” The target price for Alpha Natural is set to $8. Alpha Natural's shares closed at $8.51 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Mar 2015OppenheimerUpgradesPerformOutperform
Mar 2015Canaccord GenuityMaintainsHold
Mar 2015CRT CapitalMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (RVBD + ANR)

Around the Web, We're Loving...